Top

Quality of Life Research

Gepubliceerd in:

30-06-2016

Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson’s disease

Auteurs: Dronacharya Lamichhane, Ann L. Gruber-Baldini, Stephen G. Reich, Lisa M. Shulman

Gepubliceerd in: Quality of Life Research | Uitgave 12/2016

Abstract

Purpose

Clinical trials in Parkinson’s disease commonly employ outcome measures of disability and quality of life. Responsiveness of these outcomes measures to symptomatic decline versus improvement has not been studied. We wanted to study the responsiveness of Schwab & England Activities of Daily Living Scale (SE) and Short Form-12 (SF-12) to symptomatic decline versus improvement in Parkinson’s disease over a 4-year period among a naturalistic cohort of patients.

Methods

Parkinson’s disease patients (N = 228, disease duration 6.1 years) were followed for 4 years with assessments of disease severity, Unified Parkinson’s Disease Rating Scale (UPDRS), health-related quality of life (SF-12 physical/mental health), and disability (SE). The sample was subdivided into those who declined (N = 118) or improved (N = 102) on total-UPDRS. Responsiveness was assessed with Cohen’s effect size and standardized response mean.

Results

At baseline, patients who improved over 4 years had greater disease severity and worse quality of life than decliners (p < .05). Decliners had a 13.5-point worsening on total-UPDRS, 26.3–39.8; p < .001) associated with concomitant decline on the SF-12 (physical health 42.9–39.2, mental health 50.0–46.6; both p < .001) and the SE (85–74 %; p < .001). Improvers had a 13.0-point improvement on total-UPDRS (39.8–26.8; p < .001) associated with minimal change on the SF-12 (physical health 40.8–39.5, mental health 47.1–46.3) and SE (79–79 %). Based on effect size, the rank order of responsiveness of measures for decliners from high to low was SE (−0.78), Short Form-12 mental health (−0.45), and SF-12 physical health (−0.34). Rank order of responsiveness for improvers was Short Form-12 physical health (−0.11), SF-12 mental health (−0.10), and SE (−0.03).

Conclusions

Among decliners, measures of disability and quality of life were moderate to highly responsive to change in disease severity. Among improvers, both disability and quality of life were poorly responsive despite UPDRS improvement of comparable magnitude.

vorige artikel Associations between daily physical activity, handgrip strength, muscle mass, physical performance and quality of life in prefrail and frail community-dwelling older adults

volgende artikel QOL and sociodemographic factors among first-time parents in Japan: a multilevel analysis

Shulman, L. M. (2010). Understanding disability in Parkinson’s disease. Movement Disorders, 25(S1), S131–S135. doi:10.1002/mds.22789.CrossRefPubMed

Cella, D. F. (1995). Measuring quality of life in palliative care. Seminars in Oncology, 22(2 Suppl 3), 73–81.PubMed

Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Herlofson, K., & Alves, G. (2008). Predictors and course of health-related quality of life in Parkinson’s disease. Movement Disorders, 23(10), 1420–1427. doi:10.1002/mds.22121.CrossRefPubMed

Karlsen, K. H., Tandberg, E., Arsland, D., & Larsen, J. P. (2000). Health related quality of life in Parkinson’s disease: A prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 69(5), 584–589.CrossRefPubMedPubMedCentral

Hely, M. A., Morris, J. G. L., Traficante, R., Reid, W. G. J., O’Sullivan, D. J., & Williamson, P. M. (1999). The Sydney multicentre study of Parkinson’s disease: Progression and mortality at 10 years. Journal of Neurology, Neurosurgery and Psychiatry, 67(3), 300–307. doi:10.1136/jnnp.67.3.300.CrossRefPubMedPubMedCentral

Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005). Sydney Multicenter Study of Parkinson’s disease: Non-L-dopa-responsive problems dominate at 15 years. Movement Disorders, 20(2), 190–199. doi:10.1002/mds.20324.CrossRefPubMed

Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008). The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Movement Disorders, 23(6), 837–844. doi:10.1002/mds.21956.CrossRefPubMed

Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2007). Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain, 130(7), 1787–1798. doi:10.1093/brain/awm111.CrossRefPubMed

Vu, T. C., Nutt, J. G., & Holford, N. H. G. (2012). Progression of motor and nonmotor features of Parkinson’s disease and their response to treatment. British Journal of Clinical Pharmacology, 74(2), 267–283. doi:10.1111/j.1365-2125.2012.04192.x.CrossRefPubMedPubMedCentral

10.

Evans, J. R., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2011). The natural history of treated Parkinson’s disease in an incident, community based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 82(10), 1112–1118. doi:10.1136/jnnp.2011.240366.CrossRefPubMed

11.

Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed

12.

Hauser, R. A., Hsu, A., Kell, S., Espay, A. J., Sethi, K., Stacy, M., et al. (2013). Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: A phase 3 randomised, double-blind trial. The Lancet Neurology, 12(4), 346–356. doi:10.1016/S1474-4422(13)70025-5.CrossRefPubMed

13.

Stocchi, F., Hsu, A., Khanna, S., Ellenbogen, A., Mahler, A., Liang, G., et al. (2014). Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism and Related Disorders, 20(12), 1335–1340. doi:10.1016/j.parkreldis.2014.08.004.CrossRefPubMed

14.

Fahn, S., Elton, R., & Members of the UPDRS Development Committee. (1987). Unified Parkinson’s Disease Rating Scale. In S. Fahn, C. D. Marsden, D. B. Calne & M. Goldstein (Eds.), Recent developments in Parkinson’s disease (Vol. 2, pp. 153–164). Forest Park, NJ: Macmillan Health Care Information.

15.

Martínez-Martín, P., Gil-Nagel, A., Gracia, L. M., Gómez, J. B., Martínez-Sarriés, J., & Bermejo, F. (1994). Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Movement Disorders, 9(1), 76–83. doi:10.1002/mds.870090112.CrossRefPubMed

16.

Schwab, R. S., & England, A. C. (1969). Projection technique for evaluating surgery in Parkinson’s disease. In F. J. Gillingham & I. M. L. Danoldson (Eds.), Third symposium on Parkinson’s disease (pp. 152–157). Edinburgh: Churchill Livingstone.

17.

Ware, J., Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.CrossRefPubMed

18.

Pelle, A. J., Kupper, N., Mols, F., & de Jonge, P. (2013). What is the use? Application of the short form (SF) questionnaires for the evaluation of treatment effects. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 22(6), 1225–1230. doi:10.1007/s11136-012-0266-8.CrossRef

19.

Martinez-Martin, P., Jeukens-Visser, M., Lyons, K. E., Rodriguez-Blazquez, C., Selai, C., Siderowf, A., et al. (2011). Health-related quality-of-life scales in Parkinson’s disease: Critique and recommendations. Movement Disorders, 26(13), 2371–2380. doi:10.1002/mds.23834.CrossRefPubMed

20.

Martinez-Martin, P., Prieto, L., & Forjaz, M. J. (2006). Longitudinal metric properties of disability rating scales for Parkinson’s disease. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 9(6), 386–393. doi:10.1111/j.1524-4733.2006.00131.x.CrossRef

21.

Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17(5), 427–442.CrossRefPubMed

22.

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.CrossRefPubMed

23.

Pahwa, R., Lyons, K. E., Hauser, R. A., Fahn, S., Jankovic, J., Pourcher, E., et al. (2014). Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Related Disorders, 20(2), 142–148. doi:10.1016/j.parkreldis.2013.08.017.CrossRefPubMed

24.

Linn, B. S., Linn, M. W., & Gurel, L. (1968). Cumulative illness rating scale. Journal of the American Geriatrics Society, 16(5), 622–626.CrossRefPubMed

25.

Cohen, J. (1998). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: Lawrence Earlbaum Associates.

26.

Liang, M. H. (1995). Evaluating measurement responsiveness. The Journal of Rheumatology, 22(6), 1191–1192.PubMed

27.

Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., & Weiner, W. J. (2010). The clinically important difference on the unified Parkinson’s disease rating scale. Archives of Neurology, 67(1), 64–70. doi:10.1001/archneurol.2009.295.CrossRefPubMed

28.

Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006). Minimal clinically important change on the unified Parkinson’s disease rating scale. Movement Disorders, 21(8), 1200–1207. doi:10.1002/mds.20914.CrossRefPubMed

29.

Hauser, R. A., Gordon, M. F., Mizuno, Y., Poewe, W., Barone, P., Schapira, A. H., et al. (2014). Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinson’s Disease, 2014(2014), e467131. doi:10.1155/2014/467131.

30.

Merola, A., Zibetti, M., Angrisano, S., Rizzi, L., Ricchi, V., Artusi, C. A., et al. (2011). Parkinson’s disease progression at 30 years: A study of subthalamic deep brain-stimulated patients. Brain, 134(Pt 7), 2074–2084. doi:10.1093/brain/awr121.CrossRefPubMed

31.

Zibetti, M., Merola, A., Rizzi, L., Ricchi, V., Angrisano, S., Azzaro, C., et al. (2011). Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson’s disease. Movement Disorders, 26(13), 2327–2334. doi:10.1002/mds.23903.CrossRefPubMed

32.

Duarte, J., García Olmos, L. M., Mendoza, A., & Clavería, L. E. (2013). The natural history of Parkinson’s disease in the province of Segovia: Mortality in a longitudinal study (20-year follow-up). Acta Neurologica Scandinavica, 127(5), 295–300. doi:10.1111/ane.12003.CrossRefPubMed

33.

Ringash, J., O’Sullivan, B., Bezjak, A., & Redelmeier, D. A. (2007). Interpreting clinically significant changes in patient-reported outcomes. Cancer, 110(1), 196–202. doi:10.1002/cncr.22799.CrossRefPubMed

34.

Cella, D., Hahn, E. A., & Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Quality of Life Research, 11(3), 207–221.CrossRefPubMed

35.

Sprangers, M. A., & Schwartz, C. E. (1999). Integrating response shift into health-related quality of life research: A theoretical model. Social Science and Medicine (1982), 48(11), 1507–1515.CrossRef

36.

Tubach, F., Dougados, M., Falissard, B., Baron, G., Logeart, I., & Ravaud, P. (2006). Feeling good rather than feeling better matters more to patients. Arthritis Care and Research, 55(4), 526–530. doi:10.1002/art.22110.CrossRefPubMed

37.

Lang, A. E., Eberly, S., Goetz, C. G., Stebbins, G., Oakes, D., Marek, K., et al. (2013). Movement disorder society unified Parkinson disease rating scale experiences in daily living: Longitudinal changes and correlation with other assessments. Movement Disorders, 28(14), 1980–1986. doi:10.1002/mds.25671.CrossRefPubMed

38.

Middel, B., & van Sonderen, E. (2002). Statistical significant change versus relevant or important change in (quasi) experimental design: Some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. International Journal of Integrated Care, 2, e15.CrossRefPubMedPubMedCentral

Titel: Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson’s disease
Auteurs: Dronacharya Lamichhane
Ann L. Gruber-Baldini
Stephen G. Reich
Lisa M. Shulman
Publicatiedatum: 30-06-2016
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 12/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-016-1351-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 12/2016

Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event Log

A systematic review of measurement properties of the instruments measuring health-related quality of life in patients with irritable bowel syndrome

QOL and sociodemographic factors among first-time parents in Japan: a multilevel analysis

Interpretation of verbal descriptors for response options commonly used in verbal rating scales in patient-reported outcome instruments

Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data

Association of circulating 25-hydroxyvitamin D with mental well-being in a population-based, nationally representative sample of German adolescents